Tebipenem pivoxil/tebipenem: Carbapenem antibiotic

Drugs of the Future

Volumn 31, Issue 8, 2006, Pages 676-681

  Wang, Y ^a   Bolos J ^b   Serradell, N ^b  

^a Prous Science ^*  (United States)

^b PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

6 (1 HYDROXYETHYL) 4 METHYL 7 OXO 3 (5 OXO 3 PYRROLIDINYLTHIO) 1 AZABICYCLO[3.2.0]HEPT 2 ENE 2 CARBOXYLIC ACID PIVALOYLOXYMETHYL ESTER; 6 (1 HYDROXYETHYL) 4 METHYL 7 OXO 3 [1 (2 THIAZOLIN 2 YL) 3 AZETIDINYL] 1 AZABICYCLO[3.2.0]HEPT 2 ENE 2 CARBOXYLIC ACID PIVALOYLOXYMETHYL ESTER; 6 (1 HYDROXYETHYL) 4 METHYL 7 OXO 3 [1 (2 THIAZOLIN 2 YL) 3 AZETIDINYLTHIO] 1 AZABICYCLO[3.2.0]HEPT 2 ENE 2 CARBOXYLIC ACID; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAM DERIVATIVE; CARBAPENEM DERIVATIVE; CEFDINIR; CEFDITOREN; CEFDITOREN PIVOXIL; CEFPODOXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; FOSFOMYCIN; FROPENEM; IMIPENEM; LEVOFLOXACIN; ME 1211; PRODRUG; SITAFLOXACIN; TEBIPENEM PIVOXIL; TELBIPENEM; TETRACYCLINE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; LOOSE FECES; LUNG INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OTITIS MEDIA; RESPIRATORY TRACT INFECTION; REVIEW; SINUSITIS;

EID: 33750530790     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2006.031.08.1015461     Document Type: Review

References (27)

1. Abe, T., Hayashi, K., Mihira, A. et al. L-084, a new oral carbapenem: Synthesis and structure-activity relationships of C2-substituted 1beta-methylcarbapenems. 38th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 24-27, San Diego) 1998, Abst F-64.
2. Isoda, T., Sato, C., Mihira, A., Tamai, S., Kumagai, T. (Wyeth-Lederle Japan, Ltd.). 2-(1-(1,3-Thiazolin-2-yl)azetidin-3-yl)thiocarbapenem derivatives. EP 0632039, EP 0717042, JP 1996053453, US 5534510, US 5659043, US 5783703.
3. Kumagai, T. (Wyeth-Lederle Japan, Ltd.). Carbapenem-3-carboxylic acid ester derivatives. EP 0808315, JP 1999504039, US 5886172, WO 9721712.
4. Yasuda, S., Okue, M., Hori, N. (Meiji Seika Kaisha, Ltd.). Process for producing carbapenem derivative and intermediate for use in the production. WO 2004035539.
5. Nishino, K., Koga, T. (Kaneka Corporation). Process for producing carbapenem compound for oral administration. EP 1580191.
6. Hayashi, K., Sato, C., Hiki, S., Kumagai, T., Tamai, S., Abe, T., Nagao, Y. Novel efficient synthesis of 1-azabicyclo[1.1.0]butane and its application to the synthesis of 1-(1,3-thiazolin-2-yl)azetidine-3-thiol useful for the pendant moiety of an oral 1beta-methyl-carbapenem antibiotic L-084. Tetrahedron Lett 1999, 40(19): 3761-4.
7. Updated antibacterial efficacy of tebipenem pivoxil presented at ICAAC. DailyDrugNews.com December 27, 2005.
8. Kobayashi, R., Konomi, M., Hasegawa, K., Morozumi, M., Sunakawa, K., Ubukata, K. In vitro activity of tebipenem, a new oral carbapenem antibiotic, against penicillin-nonsusceptible Streptococcus pneumoniae. Antimicrob Agents Chemother 2005, 49(3): 889-94.
9. Kato, N., Kato, H., Tanaka, K., Watanabe, K. L-084, a new oral carbapenem: In vitro activity against anaerobic bacteria. 38th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 24-27, San Diego) 1998, Abst F-70.
10. Hanaki, H., Sasaki, K., Inaba, Y., Hori, N., Hiramatsu, K. L-084, a new oral carbapenem: In vitro activity against clinical isolated strains including vancomycin low-restraint Staphylococcus aureus and its binding affinity to PBPs. 38th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 24-27, San Diego) 1998, Abst F-66.
11. Hikida, M., Itahashi, K., Igarashi, A., Shiba, T., Kitamura, M. In vitro antibacterial activity of LJC 11,036, an active metabolite of L-084, a new oral carbapenem antibiotic with potent antipneumococcal activity. Antimicrob Agents Chemother 1999, 43(8): 2010-6.
12. Hikida, M., Itahashi, K., Shiba, T., Kitamura, M. L-084, a new oral carbapenem: In vitro antibacterial activity. 38th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 24-27, San Diego) 1998, Abst F-65.
13. Muratani, T., Kobayashi, T., Matsumoto, T. In vitro activities of tebipenem against Enterobacteriaceae isolated with broad-spectrum beta-lactamase. 45th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Dec 16-19, Washington, D.C.) 2005, Abst F-1160.
14. Nishino, T., Yoshida, M., Otsuki, M. L-084, a new oral carbapenem: In vitro activity. 38th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 24-27, San Diego) 1998, Abst F-67.
15. Igarashi, A., Hikida, M., Ubukata, K. L-084, a new oral carbapenem: Comparative antimicrobial activity of carbapenem with other beta-lactams for clinically isolated organisms. 38th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 24-27, San Diego) 1998, Abst F-68.
16. Inque, M., Kuga, A., Sato, Y., Okamoto, R. L-084, a new oral carbapenem: In vitro antibacterial activity against clinical isolates of beta-lactamase producers. 38th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 24-27, San Diego) 1998, Abst F-63.
17. Hikida, M., Itahashi, K. Igarashi, A., Kumagai, T. Susceptibilities of causative organisms of respiratory tract infections to L-084, a new oral carbapenem owing to medium pH and serum. 39th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 26-29, San Francisco) 1999, Abst 387.
18. Miyazaki, S., Hosoyama, T., Furuya, N. et al. L-084, a new oral carbapenem: In vitro and in vivo antibacterial activity. 38th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 24-27, San Diego) 1998, Abst F-69.
19. Miyazaki, S., Hosoyama, T., Furuya, N. et al. In vitro and in vivo antibacterial activities of L-084, a novel oral carbapenem, against causative organisms of respiratory tract infections. Antimicrob Agents Chemother 2001, 45(1): 203-7.
20. Itahashi, K., Fukushima, T., Nagura, J., Suzumoto, M., Shimada, J., Yamanaka, N. Efficacy of tebipenem pivoxil (ME1211) on acute otitis media in chinchilla caused by penicillin-resistant Streptococcus pneumoniae (PRSP). 45th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Dec 16-19, Washington, D.C.) 2005, Abst B-738.
21. Sugano, T., Morita, J., Yoshida, T. et al. Unique pharmacokinetic/ pharmacodynamic property of a novel carbapenem, tebipenem in murine thigh and lung infection models. 45th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Dec 16-19, Washington, D.C.) 2005, Abst F-1448.
22. Totsuka, K., Furukawa, M., Furuya, N., Yamanaka, N., Suzuki, K., Ubukata, K., Baba, S. PK/PD analysis of tebipenem pivoxil (ME1211), a novel oral carbapenem, in otolaryngological infections, a phase II clinical trial (3). 45th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Dec 16-19, Washington, D.C.) 2005, Abst L-579.
23. Yokokawa, M., Yano, M., Nakashima, M. L-084, a new oral carbapenem: Pharmacokinetics and tolerance observed in the phase I studies. 39th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 26-29, San Francisco) 1999, Abst 388.
24. Liu, C.-X., Kato, N., Watanabe, K., Sakata, T., Kaneko, T. Impact of a new quinolone, DU-6859a, and two oral carbapenems, CS-834 and L-084, on the rat and mouse caecal microflora. J Antimicrob Chemother 2000, 46(5): 823-6.
25. Liu, C., Kato, N., Watanabe, K. Impact of a new quinolone and two oral carbapenems on the rat and mouse cecum flora. 100th Gen Annu Meet Am Soc Microbiol (ASM) (May 21-25, Los Angeles) 2000, Abst A-9.
26. Ubukata, K., Kobayashi, R., Morozumi, M. et al. Bacteriological efficacy of tebipenem povoxil (ME1211), a novel oral carbapenem, in otolaryngological infections, a phase II clinical trial (2). 45th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Dec 16-19, Washington, D.C.) 2005, Abst L-578.
27. Yamanaka, N., Furukawa, M., Furuya, N., Suzuki, K., Totsuka, K., Ubukata, K., Baba, S. Clinical efficacy of tebipenem pivoxil (ME1211), a novel oral carbapenem, in otolaryngological infections, a phase II clinical trial (1). 45th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Dec 16-19, Washington, D.C.) 2005, Abst L-577.